A consumer guide published by Racine County Eye lists seven research peptides discussed in connection with post-menopausal biology, and it is more candid than most about how far apart the evidence sits from one compound to the next. It also says plainly that research peptides are laboratory materials, not products for human consumption.

The compounds named are GHK-Cu, a copper-binding tripeptide found in human plasma; CJC-1295 paired with ipamorelin, a growth hormone-releasing hormone analog plus a separate secretagogue; BPC-157 and TB-500, both associated with tissue repair models; tesamorelin, sold as EGRIFTA; MOTS-c, a mitochondrial-derived peptide; Epithalon; and Semax. Each is tied to a different pathway, and the guide argues the research question should come before the molecule.

Why this age group

The rationale is estrogen decline and what follows it: lean mass, bone, fat distribution and sleep architecture all shifting at once. The guide cites Brincat and colleagues in Obstetrics and Gynecology, who reported that skin collagen content, skin thickness and forearm bone mineral content each showed a decline of between 1 and 2 percent per year after menopause.

Where the data actually is

One compound on the list has approval behind it. Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, and in the pivotal 412-participant trial visceral fat fell 18 percent at week 26 against 2 percent on placebo, findings from a specific clinical population that the guide says do not automatically transfer.

For CJC-1295, Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism reported dose-dependent increases in mean plasma growth hormone of 2- to 10-fold in healthy adults aged 21 to 61. A Phase 2 placebo-controlled trial of BPC-157 in acute hamstring strain, with an estimated 120 participants, has been recruiting since February 2026.

Where it runs out

MOTS-c and Epithalon rest largely on animal, cell-culture or unreplicated work, and the Epithalon literature is described as decades old and mostly Russian-language. The Semax human evidence cited is a single 2018 study of 110 post-stroke patients, mean age 58.

The hormone therapy line

The guide is firm that peptides are not substitutes for hormone therapy, quoting Stephanie Faubion of The Menopause Society that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. That is the sentence most product-adjacent roundups leave out.

Bottom line

Anita Gupta of Johns Hopkins, quoted from AARP, puts the problem cleanly: the field has to be clear about what is clinical innovation and what is hype. On this list, that line falls somewhere between tesamorelin and everything else.